Marisa Wexler, MS,  senior science writer—

The desmopressin stimulation test can be useful to diagnose Cushing’s during pregnancy, a time when its identification may be particularly challenging due to the hormonal changes these women experience, a new case report says. The report, “Desmopressin Stimulation Test in a Pregnant Patient with Cushing’s Disease,” was published…

At an upcoming conference offered by the University of Pennsylvania (Penn), experts will share the latest approaches and techniques for diagnosing and treating Cushing’s disease and other conditions caused by tumors in the pituitary gland. The “4th Pituitary Update” conference will run from 7:45 a.m. to 4 p.m. ET…

A newly discovered mutation in a gene called USP8 may contribute to the development of pituitary tumors, which are the underlying cause Cushing’s disease, researchers reported, describing the mutation. Their work also linked tumors with mutations to more aggressive disease than those without mutations. The study, “Genetic…

Analyzing small amounts of tumor DNA that end up in the bloodstream could be useful for assessing the course of Cushing’s syndrome in patients whose disease is caused by a hormone-producing tumor, a new report illustrates. In the case of a 45-year-old man in France, DNA changes “were well correlated…

People with Cushing’s disease who are treated with Isturisa (osilodrostat) should be monitored for the possibility of developing adrenal insufficiency, a report highlights. The case report, “Osilodrostat in Cushing’s disease: The risk of delayed adrenal insufficiency should be carefully monitored,” was published in the journal…

Thyrotoxicosis, or abnormally high levels of thyroid hormones in the body, is a rare complication that can occur in people with Cushing’s disease who undergo tumor-removal surgery, a new report highlights. The study, “Management of thyrotoxicosis occurring after surgery for Cushing’s disease: a case series,” was…

Measuring the levels of the RNA molecule that provides instructions to make a protein called FKBP5 could be useful for assessing cortisol activity in people with Cushing’s disease, a new study indicates. The study, “Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

The U.S. Patent and Trademark Office has issued a new patent to Strongbridge Biopharma that covers a method of using Recorlev (levoketoconazole), the company’s investigational treatment for endogenous Cushing’s syndrome, to treat people with Cushing’s who also are taking metformin for type 2 diabetes. According to a…

Xeris Pharmaceuticals and Strongbridge Biopharma have entered an agreement in which Xeris will acquire Strongbridge, forming a new entity called Xeris Biopharma Holdings. Following the transaction, Xeris also will acquire Strongbridge’s pipeline, which includes Recorlev (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome. “Strongbridge’s attractive rare…